Skip to menu Skip to content Skip to footer
Associate Professor

Simone M Goldinger

Email: 

Overview

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Qualifications

  • Bachelor (Honours) of Medicine, University of Zurich
  • Masters (Research) of Medicine and Surgery and Medical Science, University of Zurich
  • Doctoral (Research), University of Zurich
  • Professional Doctorate, University of Zurich
  • Fellow, Australasian College of Dermatologists, Australasian College of Dermatologists

Works

Search Professor Simone M Goldinger’s works on UQ eSpace

136 works between 2006 and 2025

21 - 40 of 136 works

2019

Journal Article

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

Drago, Joshua Z., Lawrence, Donald, Livingstone, Elisabeth, Zimmer, Lisa, Chen, Tianqi, Giobbie-Hurder, Anita, Amann, Valerie C., Mangana, Joanna, Siano, Marco, Zippelius, Alfred, Dummer, Reinhard, Goldinger, Simone M. and Sullivan, Ryan J. (2019). Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Research, 29 (1), 65-69. doi: 10.1097/CMR.0000000000000527

Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study

2019

Journal Article

Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma

Hogan, Sabrina A., Courtier, Anais, Cheng, Phil F., Jaberg-Bentele, Nicoletta F., Goldinger, Simone M., Manuel, Manuarii, Perez, Solene, Plantier, Nadia, Mouret, Jean-Francois, Thi Dan Linh Nguyen-Kim,, Raaijmakers, Marieke I. G., Kvistborg, Pia, Pasqual, Nicolas, Haanen, John B. A. G., Dummer, Reinhard and Levesque, Mitchell P. (2019). Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunology Research, 7 (1), 77-85. doi: 10.1158/2326-6066.CIR-18-0136

Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma

2018

Journal Article

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Tio, Martin, Rai, Rajat, Ezeoke, Ogochukwu M., McQuade, Jennifer L., Zimmer, Lisa, Khoo, Chloe, Park, John J., Spain, Lavinia, Turajlic, Samra, Ardolino, Luke, Yip, Desmond, Goldinger, Simone M., Cohen, Justine V., Millward, Michael, Atkinson, Victoria, Kane, Alisa Y., Ascierto, Paolo A., Garbe, Claus, Gutzmer, Ralf, Johnson, Douglas B., Rizvi, Hira A., Joshua, Anthony M., Hellmann, Matthew D., Long, Georgina V. and Menzies, Alexander M. (2018). Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. European Journal of Cancer, 104, 137-144. doi: 10.1016/j.ejca.2018.09.017

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

2018

Journal Article

The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe

Dimitriou, Florentia, Krattinger, Regina, Ramelyte, Egle, Barysch, Marjam J., Micaletto, Sara, Dummer, Reinhard and Goldinger, Simone M. (2018). The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. Current Oncology Reports, 20 (11) 87. doi: 10.1007/s11912-018-0732-8

The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe

2018

Journal Article

Phase I, open-label study of pasireotide in patients with <i>BRAF</i>-wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma

Dummer, Reinhard, Michielin, Olivier, Nageli, Mirjam Chantal, Goldinger, Simone M., Campigotto, Federico, Kriemler-Krahn, Ulrike, Schmid, Herbert, Pedroncelli, Alberto, Micaletto, Sara and Schadendorf, Dirk (2018). Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma. Esmo Open, 3 (5) UNSP e000388. doi: 10.1136/esmoopen-2018-000388

Phase I, open-label study of pasireotide in patients with <i>BRAF</i>-wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma

2018

Journal Article

Sarcoid-like reactions in patients receiving modern melanoma treatment

Dimitriou, Florentia, Frauchiger, Anna L., Urosevic-Maiwald, Mirjana, Naegeli, Mirjam C., Goldinger, Simone M., Barysch, Marjam, Franzen, Daniel, Kamarachev, Jivko, Braun, Ralph, Dummer, Reinhard and Mangana, Joanna (2018). Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Research, 28 (3), 230-236. doi: 10.1097/CMR.0000000000000437

Sarcoid-like reactions in patients receiving modern melanoma treatment

2018

Conference Publication

The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series

Goldinger, Simone M., Lo, Serigne, Hassel, Jessica Cecile, Forschner, Andrea, McKean, Meredith Ann, Zimmer, Lisa, Khoo, Chloe Chia Hoey, Dummer, Reinhard, Eroglu, Zeynep, Buchbinder, Elizabeth Iannotti, Ascierto, Paolo Antonio, Gutzmer, Ralf, Rozeman, Elisa A., Hoeller, Christoph, Johnson, Douglas Buckner, Gesierich, Anja, Kolblinger, Peter, Benannoune, Naima, Cohen, Justine Vanessa and Menzies, Alexander M. (2018). The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/JCO.2018.36.15_suppl.e21588

The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series

2018

Journal Article

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study (vol 91, pg 116, 2018)

Valpione, Sara, Carlino, Matteo S., Mangana, Johanna, Mooradian, Meghan J., McArthur, Grant, Schadendorf, Dirk, Hauschild, Axel, Menzies, Alexander M., Arance, Ana, Ascierto, Paolo A., Di Giacomo, AnnaMaria, de Rosa, Francesco, Larkin, James, Park, John J., Goldinger, Simone M., Sullivan, Ryan J., Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael, Rai, Rajat, Gaba, Lydia, Long, Georgina V. and Lorigan, Paul (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study (vol 91, pg 116, 2018). European Journal of Cancer, 93, 158-158. doi: 10.1016/j.ejca.2018.02.001

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study (vol 91, pg 116, 2018)

2018

Journal Article

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

Hecht, Markus, Meier, Friedegund, Zimmer, Lisa, Polat, Bulent, Loquai, Carmen, Weishaupt, Carsten, Forschner, Andrea, Gutzmer, Ralf, Utikal, Jochen S., Goldinger, Simone M., Geier, Michael, Hassel, Jessica C., Balermpas, Panagiotis, Kiecker, Felix, Rauschenberg, Ricarda, Dietrich, Ursula, Clemens, Patrick, Berking, Carola, Grabenbauer, Gerhard, Schadendorf, Dirk, Grabbe, Stephan, Schuler, Gerold, Fietkau, Rainer, Distel, Luitpold V. and Heinzerling, Lucie (2018). Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 118 (6), 785-792. doi: 10.1038/bjc.2017.489

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

2018

Journal Article

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

Valpione, Sara, Carlino, Matteo S., Mangana, Johanna, Mooradian, Meghan J., McArthur, Grant, Schadendorf, Dirk, Hauschild, Axel, Menzies, Alexander M., Arance, Ana, Ascierto, Paolo A., Di Giacomo, AnnaMaria, de Rosa, Francesco, Larkin, James, Park, John J., Goldinger, Simone M., Sullivan, Ryan J., Xu, Wen, Livingstone, Elisabeth, Weichenthal, Michael, Rai, Rajat, Gaba, Lydia, Long, Georgina V. and Lorigan, Paul (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 91, 116-124. doi: 10.1016/j.ejca.2017.12.007

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

2018

Journal Article

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma

Krahenbuhl, Lukas, Goldinger, Simone M., Mangana, Joanna, Kerl, Katrin, Chevolet, Ines, Brochez, Lieve, Horak, Christine, Levesque, Mitch, Dummer, Reinhard and Cheng, Phil F. (2018). A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. Neoplasia, 20 (2), 218-225. doi: 10.1016/j.neo.2017.12.002

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma

2017

Journal Article

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma

Amann, V. C., Hoffmann, D., Mangana, J., Dummer, R. and Goldinger, S. M. (2017). Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. Journal of the European Academy of Dermatology and Venereology, 31 (10), 1638-1640. doi: 10.1111/jdv.14268

Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma

2017

Journal Article

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab

Brueggemann, C., Kirchberger, M. C., Goldinger, S. M., Weide, B., Konrad, A., Erdmann, M., Schadendorf, D., Croner, R. S., Krahenbuhl, L., Kaehler, K. C., Hafner, C., Leisgang, W., Kiesewetter, F., Dummer, R., Schuler, G., Stuerzl, M. and Heinzerling, L. (2017). Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology, 143 (10), 1977-1984. doi: 10.1007/s00432-017-2450-2

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab

2017

Journal Article

Electrical Impedance Spectroscopy in Skin Cancer Diagnosis

Braun, Ralph P., Mangana, Johanna, Goldinger, Simone, French, Lars, Dummer, Reinhard and Marghoob, Ashfaq A. (2017). Electrical Impedance Spectroscopy in Skin Cancer Diagnosis. Dermatologic Clinics, 35 (4), 489-+. doi: 10.1016/j.det.2017.06.009

Electrical Impedance Spectroscopy in Skin Cancer Diagnosis

2017

Conference Publication

Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C

Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Koo, C., Park, J. J., Ardolino, L., Yip, D., Goldinger, S., Cohen, J. V., Millward, M., Atkinson, V., Kane, A. Y., Ascierto, P. A., Garbe, C., Gutzmer, R., Johnson, D. B., Hellman, M. D., Long, G. V. and Menzies, A. M. (2017). Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS.

Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C

2017

Conference Publication

Melanoma patients treated with Encorafenib show less hyperproliferative keratinocytic cutaneous adverse events and more intense inflammatory palmoplantar erythrodysesthesia compared to other BRAF inhibitors

Graf, N., Goldinger, S., Galliker, N., Conrad, S. and Dummer, R. (2017). Melanoma patients treated with Encorafenib show less hyperproliferative keratinocytic cutaneous adverse events and more intense inflammatory palmoplantar erythrodysesthesia compared to other BRAF inhibitors. HOBOKEN: WILEY.

Melanoma patients treated with Encorafenib show less hyperproliferative keratinocytic cutaneous adverse events and more intense inflammatory palmoplantar erythrodysesthesia compared to other BRAF inhibitors

2017

Journal Article

Interstitial granulomatous dermatitis during talimogen laherparepvec treatment

Frauchiger, Anna L., Bruggen, Marie-Charlotte, Goldinger, Simone M. and Dummer, Reinhard (2017). Interstitial granulomatous dermatitis during talimogen laherparepvec treatment. Melanoma Research, 27 (4), 400-401. doi: 10.1097/CMR.0000000000000369

Interstitial granulomatous dermatitis during talimogen laherparepvec treatment

2017

Journal Article

Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report

Murer, Carla, Kranzlin-Stieger, Pascale, French, Lars E., Dummer, Reinhard and Goldinger, Simone M. (2017). Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report. Melanoma Research, 27 (4), 396-398. doi: 10.1097/CMR.0000000000000358

Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report

2017

Journal Article

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Mangana, Joanna, Cheng, Phil F., Kaufmann, Corina, Amann, Valerie C., Frauchiger, Anna L., Stoegner, Viola, Held, Ulrike, von Moos, Roger, Michielin, Olivier, Braun, Ralph P., Levesque, Mitchell P., Goldinger, Simone M. and Dummer, Reinhard (2017). Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research, 27 (4), 358-368. doi: 10.1097/CMR.0000000000000359

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

2017

Journal Article

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Izar, Benjamin, Sharfman, William, Hodi, F. Stephen, Lawrence, Donald, Flaherty, Keith T., Amaravadi, Ravi, Kim, Kevin B., Puzanov, Igor, Sosman, Jeffrey, Dummer, Reinhard, Goldinger, Simone M., Lam, Lyhping, Kakar, Shefali, Tang, Zhongwen, Krieter, Oliver, McDermott, David F. and Atkins, Michael B. (2017). A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Medicine, 6 (8), 1904-1914. doi: 10.1002/cam4.1140

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Supervision

Availability

Associate Professor Simone M Goldinger is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Media

Enquiries

For media enquiries about Associate Professor Simone M Goldinger's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au